A Phase 1, randomized study to evaluate the safety, tolerability, and pharmacokinetics (PK) of the effects of food on the bioavailability of ONC201 following oral administration in healthy adult subjects - Part 2b
Latest Information Update: 31 Oct 2023
At a glance
- Drugs Dordaviprone (Primary)
- Indications Acute myeloid leukaemia; Adenocarcinoma; Breast cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Glioblastoma; Glioma; Liver cancer; Multiple myeloma; Myelodysplastic syndromes; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Sarcoma; Small cell lung cancer; Thyroid cancer
- Focus Adverse reactions
- Sponsors Chimerix
- 12 Sep 2023 Status changed from not yet recruiting to recruiting.
- 12 Sep 2023 Results presented at the 2023 American College of Clinical Pharmacology Annual Meeting
- 04 Aug 2021 New trial record